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eerhaps the answer to the rhetorical question, “why aren’t
ll cardiologists preventive?” lies in a quote attributed to
merican humorist W. C. Fields: “If at first you don’t
ucceed, try again. Then quit. There’s no use being a damn
ool about it.” As usual, there is truth in Fields’ statement.
eople in general, and physicians in particular, are unlikely
o repeatedly attempt that which they cannot achieve.
erhaps all cardiologists do not consider themselves “pre-
entive” because of past therapeutic failures.
Such a defense might have been plausible before the
lethora of data over the past two decades demonstrating
ot only reduction in atherosclerosis progression, but actual
therosclerosis reversal with aggressive medical and lifestyle
anagement. Four classes of drugs (statins, antiplatelet
gents, beta-blockers, and angiotensin-converting enzyme
ACE) inhibitors/angiotensin II receptor blockers [ARBs])
nd three lifestyle components (cigarette smoking cessation,
utrition, and physical activity) have produced life-saving
eductions in cardiovascular (CV) risk by modulation of
therosclerosis and CV disease pathophysiology.
Translation of this documented efficacy into clinical
ractice is our most critical need in cardiology today. With
he adoption of a universal prevention mindset, we can
ctively address the burgeoning epidemic of CV disease and
ur impending shortage of trained CV specialists.
TATIN THERAPY
he 1987 launch of lovastatin, the first approved hydroxy
ethyl glutaryl-coenzyme A-reductase inhibitor, and the
ubsequent introduction of more powerful and therapeuti-
ally effective statins not only revolutionized treatment of
atients with frank hyperlipidemia but also radically
hanged the treatment of at-risk patients. A solid body of
vidence has demonstrated that statins reduce the risk of
V events in patients with established CV disease, patients
t risk for CV disease due to cardiac risk factors, and even
oncomitant vascular disease (1). The magnitude of riskp
*Throughout his Presidential year, Dr. Wolk will present ideas important to
ollege members, in collaboration with key ACC leaders and staff.eduction is on the order of 30%, and cost analyses calculate
uperior cost utility over other CV treatments such as
evascularization interventions (2).
Accordingly, the National Cholesterol Education Pro-
ram Adult Treatment Panel (NCEP ATP) III guidelines
ecently released an update stating that a low-density
ipoprotein cholesterol goal of 70 mg/dl is a reasonable
herapeutic strategy for patients at very high cardiac risk,
uch as those with known coronary artery disease, diabetes,
he metabolic syndrome, or a recent cardiac event (3).
NTIPLATELET THERAPY
spirin and other antiplatelet agents have been shown to be
ffective in preventing myocardial infarction (MI) at all CV
isk levels studied. Aspirin, an inexpensive over-the-counter
reatment, has a large body of evidence documenting its
tility for risk reduction in patients with established CV
isease (4). The overall magnitude of risk reduction in terms
f death and non-fatal MI is approximately 25%. The
vidence of effectiveness among at-risk patients encom-
asses studies of more than 55,000 subjects with cardiac risk
actors (5). The consistency of MI reduction in these clinical
rials highlights the reliability and homogeneity of these
ndings that patients at moderate risk can also benefit from
spirin therapy. Current American College of Cardiology/
merican Heart Association (ACC/AHA) guidelines indi-
ate that low-dose aspirin therapy (81 to 325 mg daily) is
ndicated for all patients with established CV disease, as
ell as for patients deemed at moderate risk (10% 10-year
alculated global risk). Cost-analysis evaluation of aspirin
herapy demonstrates actual cost savings among these pa-
ient groups (6), a remarkable finding given ever-escalating
ealth care costs.
ETA-BLOCKER THERAPY
ore than 20 randomized controlled trials demonstrate the
fficacy of beta-blocker therapy for the reduction of adverse
vents in patients with CV disease, as well as for at-risk
atients undergoing surgery and anesthesia (7). Used in the
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ailure, the overall risk reduction is 25%. Subgroup popula-
ions also appear to benefit, including diabetics and patients
ith heart failure (8). The ACC/AHA guidelines call for
he widespread use of beta-blockers in eligible CV disease
atients (9). Many beta-blockers are now available in more
ffordable generic formulations.
CE INHIBITOR/ARB THERAPY
urrent ACC/AHA guidelines for secondary prevention in
stablished coronary heart disease include beta-blocker use
nd strong consideration of ACE inhibitor use independent
f hypertensive status (10). The guidelines suggest that
hese options also might be used as first-line medications in
ypertensive coronary artery disease patients and diabetics.
he seventh report of the Joint National Committee ex-
anded this primary ACE inhibitor recommendation to
ypertension in the setting of heart failure, post-MI, high
oronary risk, diabetes, chronic kidney disease, and recur-
ent stroke prevention (9). The overall magnitude of risk
eduction in terms of death and non-fatal MI is approxi-
ately 25%.
The ARBs have been intensively studied since the 1990s;
hey prevent the pathophysiologic effects mediated by the
ngiotensin II type 1 receptor when angiotensin II binds to
t, thus blocking vasoconstriction, sodium absorption, aldo-
terone release, and vascular smooth muscle remodeling.
he ARBs can probably be used interchangeably with ACE
nhibitors, especially in patients with an ACE inhibitor-
nduced cough.
IFESTYLE THERAPY
omprehensive lifestyle change can sharply reduce CV risk.
pecifically, cigarette smoking cessation (11), nutrition (12),
nd physical activity (13) can reduce risk of adverse events to
greater magnitude than medication, ranging from 50% for
moking cessation and nutrition to 20% to 25% for exercise.
y controlling food intake and increasing exercise, patients
an meaningfully alter their body mass index and affect their
ebilitating obesity. Such a concerted, combined effort also
as a direct and positive impact on other manageable disease
tates, such as diabetes, that have been linked to heart stress
14).
Encouraging and achieving sustained lifestyle change
emains a challenge for the physician and patient. However,
ew commercially available programs can provide patients
ith supportive medical supervision and case management
n person, by telephone, or online. Such programs now have
ocumented track records of assisting patients with long-
erm lifestyle and risk factor change (15). pOMPREHENSIVE
GGRESSIVE MEDICAL MANAGEMENT
ummary studies document the potent utility of combining
ll of these modalities for maximal CV risk reduction.
ukerjee et al. (16) observed a more than 90% reduction of
eath and recurrent event risk in the year following an acute
oronary syndrome/MI among patients who were pre-
cribed a statin, aspirin, beta-blocker, or ACE inhibitor.
espite these compelling data, national survey data indicate
hat only a minority of patients eligible by guidelines for
hese therapies in fact receives them (17).
MPLICATIONS
iven this large body of clinical trial evidence documenting
he utility of aggressive medical management to both
revent and reverse CV disease, this treatment gap has
normous implications for the training and practice of
ardiology. First, it is time that all CV specialists recognize
hey must be “preventive cardiologists.” We all need to push
he paradigm from “intervention to prevention,” working
irelessly to protect patients who are still healthy rather than
reating rampant heart disease.
Second, training programs must prepare all cardiologists
or the practice of prevention. Current ACC guidelines for
ardiology training designate a minimum of a one-month
or longer) rotation in preventive CV medicine (18). Nota-
ly, an ACC survey conducted in 2000 found that although
ssentially all training programs had adequate facilities and
aculty to provide this training, a minority (only 30%)
ctually performed the training (18).
Finally, it is time to re-evaluate what we “know” about
anaging cardiac patients now that we have so much new
ata on heart disease prevention. All of us consider signif-
cant three-vessel disease as an indication for aggressive
evascularization therapy on the basis of results from such
tudies as the Coronary Bypass Surgery Study (CASS). The
ASS and other studies are anchored in science and clinical
ata that are now decades old and that predate the statin-
revention revolution. Perhaps it is time to redo such studies
nd compare revascularization with “standard medical care,”
hich must now include aggressive preventive strategies.
Cardiology must continue to evolve from the observa-
ional world of the 1960s to very aggressive intervention to
position of proactive prevention. Many cardiologists have
uch invested in the interventional treatment of CV dis-
ase, yet the evolution to a more preventive approach is
nevitable. It will not come painlessly, and not without
dditional modern outcome studies testing the latest and
ost aggressive prevention strategies.
While we await these updated studies, all cardiologists
hould hear the call to be just as aggressive with prevention
s they were with intervention. Experiential learning with
revention has been replaced with hard data reinforcing
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